Image credit: Medtronic
On September 19, 2025, Medtronic announced that it had received FDA approval for its Altaviva implantable tibial nerve neurostimulator for the treatment of urge urinary incontinence (UUI). The device is inserted near the ankle during a minimally invasive procedure that doesn’t require sedation or imaging, and is then activated to deliver therapy automatically.
The device is powered by a rechargeable battery based on Medtronic’s proprietary Overdrive™ battery technology with an expected longevity of 15 years. According to Medtronic, the Altaviva IPG only needs to be recharged 1–2 times per year under standard therapy settings, with each session taking about 30 minutes when properly positioned.